Patient Selection for Adjuvant Therapy in EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss key considerations in selecting patients for adjuvant targeted therapy in early-stage EGFR-mutated non–small cell lung cancer (NSCLC), particularly those with multiple comorbidities. Dr. Kim highlights that while comorbid conditions are common in this patient population, many are manageable and should not automatically preclude treatment. The discussion emphasizes the importance of evaluating overall functional status, performance status, and the ability to tolerate therapy rather than relying solely on age or comorbidity burden. Dr. Kim also notes that proactive management of underlying conditions and close monitoring during treatment can help support safe therapy delivery. The panel underscores the need for individualized risk–benefit assessment and shared decision-making when recommending adjuvant therapy. This segment reinforces that appropriate patient selection is critical to optimizing outcomes in early-stage EGFR-mutated NSCLC.